[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-370293-en":59,"doc-seo-370293-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},370293,8796095461564,"Liam","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma","Pan-cancer data were used to define the expression landscape, prognostic relevance, and roles of ADAM12 in the tumor immune microenvironment, with a focused in-depth analysis in glioma. The study reports marked ADAM12 overexpression in glioma tissues, links higher expression to enhanced glioma malignancy, and associates ADAM12 with poorer patient outcomes. Findings support ADAM12 as a biomarker for predicting glioma aggressiveness and prognosis, and as a potential therapeutic target. ","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma  \nPeng Lv1,2,3, Yanbin Zhang1,3, Wenjie Wu1,3, Xiaobing Jiang1􀀍 & Wei Xiang1􀀍  \nADAM12, part ofthe adisintegrin and metalloproteases (ADAMs) family, has been widely reported in recent years to be associated with various malignant tumor behaviors, including migration, invasion, and treatment resistance. However, its role at the pan-cancer level remains insufficiently characterized. In this study, pan-cancer data were utilized to elucidate the expression patterns, prognostic significance, and potential roles of ADAM12 within the tumor immune microenvironment. An in-depth analysis of ADAM12 in gliomas was also conducted. Our findings revealed that ADAM12 expression is markedly overexpressed in glioma tissues, enhances glioma cell malignancy, and is associated with a worse prognosis. These results suggest that ADAM12 may serve as a biomarker for predicting glioma malignancy and patient prognosis, as well as a potential therapeutic target in glioma treatment.  \nKeywords ADAM12, Pan-cancer, Glioma, Biomarker, Immune microenvironment  \nCancer remains one of the leading causes of mortality worldwide. While cancer incidence rates vary across countries with differing income levels, it negatively impacts life expectancy in all regions1. Traditional cancer treatments primarily include surgical resection, chemotherapy, and radiotherapy. However, recent advances have led to the development of new treatments, such as immunotherapy and oncolytic viruses2–4. Despite these advancements, the heterogeneity among patients with different cancers remains a significant challenge. For instance, CAR-T therapy has shown promising results in hematological tumors but faces challenges in treating solid tumors5–7. Additionally, patients with the same tumor type can exhibit varying responses to the same treatment2,8. Although cancer types differ in their mechanisms of development, they share common characteristics, such as uncontrolled proliferation, increased invasiveness, and immune evasion9. Therefore, pan-cancer studies may uncover both commonalities and differences among cancers, potentially leading to the identification of novel therapeutic targets and biomarkers.  \nA disintegrin and metalloprotease (ADAM) family consists of transmembrane and secreted proteins characterized by metalloprotease domains10. These proteins are involved in cell adhesion and the hydrolytic processing of the ectodomains of various cell-surface receptors and signaling molecules10, 11. They play a crucial role in regulating cellular behaviors, such as cell adhesion, migration, protein hydrolysis, and signaling12–15. ADAM12, a member of this family, has been shown to play a pro-carcinogenic role in various cancers. It promotes the migration and invasion of breast cancer cells16, the proliferation of hepatocellular carcinoma cells17, and the resistance of rectal cancer cells to radiotherapy18. Nevertheless, most studies on ADAM12 have focused on individual cancer types, failing to provide a comprehensive overview at the pan-cancer level.  \nIn this study, multi-omics data were used to explore the potential role and prognostic value of ADAM12 in pan-cancer, with a particular focus on gliomas. Experimental validation revealed that ADAM12 expression is upregulated in glioma tissues and promotes glioma cells proliferation, migration, and invasion. These findings suggest that ADAM12 this study, multi-omics data were used to explore the potential role and prognostic value of ADAM12 in pan-cancer, with a particular focus on gliomas. Experimental validation revealed that ADAM12 could be a potential therapeutic target for glioma treatment.  \n1Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue NO.1277, Wuhan 430022, Hubei Prov","cbCaic846sqUKTeI","https://ap.wps.com/l/cbCaic846sqUKTeI","pdf",10275203,18,"English","en",105,"# Materials and methods\n## Acquisition of data sources\n## Diagnostic and prognostic analysis","[{\"question\":\"What is ADAM12 and why was it studied in this work?\",\"answer\":\"ADAM12 is a member of the ADAM (a disintegrin and metalloprotease) family. The study investigates its pan-cancer expression patterns and its potential functions in the tumor immune microenvironment.\"},{\"question\":\"How does ADAM12 expression relate to glioma outcomes?\",\"answer\":\"ADAM12 is markedly overexpressed in glioma tissues, correlates with increased glioma malignancy, and is associated with a worse prognosis.\"},{\"question\":\"What analytical strategy was used to evaluate diagnostic and prognostic value?\",\"answer\":\"Prognostic significance was assessed using overall survival and disease-specific survival from TCGA, diagnostic potential was evaluated with ROC analysis in GBMLGG, and Cox analyses were performed to test prognostic associations.\"}]","Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma | PDF",1790187814,45,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c9a401a0acf736b13dbfad03ff3b157.webp",983,1291,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/357bc1c95167a03d2780ad21484f8f00.webp",982,1290,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b9918bd2bc024552dbdc216e22a8800.webp",981,1289,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8d900f605cd6154262b63d14546c252.webp",980,1287,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"pan-cancer-analysis-identifies-adam12-as-a-prognostic-biomarker-and-indicator-of-immune-infiltration-in-glioma","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/pan-cancer-analysis-identifies-adam12-as-a-prognostic-biomarker-and-indicator-of-immune-infiltration-in-glioma/370293/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-identifies-adam12-as-a-prognostic-biomarker-and-indicator-of-immune-infiltration-in-glioma/370293.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":136,"interactionType":137,"userInteractionCount":24},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"What is ADAM12 and why was it studied in this work?","Question",{"text":146,"@type":147},"ADAM12 is a member of the ADAM (a disintegrin and metalloprotease) family. The study investigates its pan-cancer expression patterns and its potential functions in the tumor immune microenvironment.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"How does ADAM12 expression relate to glioma outcomes?",{"text":151,"@type":147},"ADAM12 is markedly overexpressed in glioma tissues, correlates with increased glioma malignancy, and is associated with a worse prognosis.",{"name":153,"@type":144,"acceptedAnswer":154},"What analytical strategy was used to evaluate diagnostic and prognostic value?",{"text":155,"@type":147},"Prognostic significance was assessed using overall survival and disease-specific survival from TCGA, diagnostic potential was evaluated with ROC analysis in GBMLGG, and Cox analyses were performed to test prognostic associations.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790216912]